Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03529110
Title DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Daiichi Sankyo
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS


No variant requirements are available.